Sign in

    Andy Shah

    Senior Analyst at William Blair & Company

    Andy Shah is a Senior Analyst at William Blair & Company specializing in equity research, though publicly available records do not provide details on his specific company coverage or quantitative performance metrics. His professional background traces back to prior roles in investment analysis and related fields, but there is no verified information about previous employers or a detailed career timeline. Certifications and regulatory credentials, such as FINRA registration or securities licenses, are not confirmed through publicly accessible sources. At present, there are no notable third-party recognitions or rankings attributed to Andy Shah, and concrete data on his track record or return rates is unavailable.

    Andy Shah's questions to Altimmune (ALT) leadership

    Andy Shah's questions to Altimmune (ALT) leadership • Q1 2025

    Question

    Andy Shah of William Blair inquired about the degree of overlap between the clinical trial sites used for the MASH and obesity programs and the sites planned for the upcoming AUD and ALD trials.

    Answer

    An Altimmune executive stated that while there is 'some overlap' between the site networks due to the commonality of obesity in these patient populations, he could not provide specific data on the percentage of overlapping sites at this time.

    Ask Fintool Equity Research AI

    Andy Shah's questions to Cardiff Oncology (CRDF) leadership

    Andy Shah's questions to Cardiff Oncology (CRDF) leadership • Q2 2024

    Question

    Andy Shah asked about the scientific validation for switching the pancreatic cancer trial to a NALIRIFOX combination, particularly regarding drug synergy, and inquired if the company is exploring preclinical combinations of onvansertib with antibody-drug conjugates (ADCs) for ovarian cancer.

    Answer

    Executive Mark Erlander stated that the known synergy between onvansertib and irinotecan (a key component of NALIRIFOX) was a primary driver for the change in the pancreatic cancer trial. He also noted the lead investigator's prior positive experience with the drug. Regarding the pipeline, Erlander confirmed that Cardiff Oncology is actively conducting preclinical work combining onvansertib with ADCs, not only for ovarian cancer but for other indications as well.

    Ask Fintool Equity Research AI